An interventional study of Diazepam in Alcoholism, sponsored by University Hospital, Lille. Completed at 2 sites in France. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by University Hospital, Lille · Not applicable, Interventional, and Treatment
Alcohol-dependence is a medical condition that can lead to the occurrence of an alcohol withdrawal syndrome (AWS) in case of alcohol drinking cessation. Diazepam is the reference medication for preventing or treating AWS. The recommended average diazepam treatment duration is usually around one week, and this duration is generally not considered to impact the subsequent relapse rate in alcohol drinking.
However, several previous studies have found that patients experienced frequent anxious symptoms during the weeks following detoxification. Such symptoms may foster early relapse in alcohol drinking. Furthermore, it has been suggested that this anxiety could pertain to late withdrawal symptoms.
The DIAMA study hypothesizes that extending the diazepam detoxification treatment to one month can significantly reduce the cumulated relapse rate in alcohol drinking over the three following months.
1,606 studies on the registry are indexed under Alcoholism; 329 are open to participants now.
This study's enrollment of 26 is below the median of 87 across 1,371 interventional studies indexed under Alcoholism.
Browse Alcoholism studies →University Hospital, Lille is the lead sponsor of 625 studies on the registry; 141 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Diazepam treatment duration will not exceed 10 days (commonly recommended duration for alcohol detoxification).
Drug: Diazepam
Diazepam will be slowly tapered to be stopped at day 30
Drug: Diazepam
40 mg per day.
Rate of relapse in alcohol drinking
Proportion of patients who will have reported any alcohol drinking over the three months following the beginning of the detoxification procedure (using the alcohol timeline follow-back method).
Time frame: at 3 months
Occurrence of adverse events
Time frame: Over the first month, at 3 months
Rate of relapse in heavy drinking
Proportion of patients who will have reported at least one heavy drinking day, i.e., ≥ 50 g of alcohol in a day, over the first month and the three month following the beginning of the detoxification procedure (using the alcohol timeline follow-back method).
Time frame: at 1 month; at 3 months
Ratio of drinking days/heavy drinking days
Time frame: over the first month, at 3 months
Level of self-reported anxiety
Score of self-reported anxiety using the State-Trait Anxiety Inventory
Time frame: at 1 month; at 3 months
Level of clinician-assessed anxiety
Score of anxiety using the Hamilton Anxiety Rating Scale
Time frame: at 1 month; at 3 months
Level of alcohol craving
Level of alcohol craving using the Obsessive-Compulsive Drinking Scale
Time frame: at 1 month; at 3 months
Average weekly alcohol consumption
Time frame: at 1 month; at 3 months
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Lille